Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ATM |
| Variant | A2524P |
| Impact List | missense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | ATM A2524P lies within the FAT domain of the Atm protein (UniProt.org). A2524P results in Atm expression similar to wild-type but decreased DNA damage-induced kinase activity in patient samples (PMID: 17166884), fails to rescue survival and proliferation of ATM-haploid cells upon olaparib treatment in a high-throughput cell culture assay (PMID: 40580951), and therefore, is predicted to lead to a loss of Atm protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
ATM mutant ATM inact mut ATM A2524P |
| Transcript | NM_000051.4 |
| gDNA | chr11:g.108331498G>C |
| cDNA | c.7570G>C |
| Protein | p.A2524P |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_017017790.3 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_006718843.5 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| NM_001351834.2 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_011542843.2 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_006718843.4 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_011542840.3 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_017017789.2 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| NM_000051.3 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_011542843.3 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_047426976.1 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_047426975.1 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| NM_000051.4 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_017017790.2 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_011542840.4 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_005271562.6 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| NM_001351834.1 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| XM_005271562.5 | chr11:g.108331498G>C | c.7570G>C | p.A2524P | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM A2524P | Advanced Solid Tumor | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lynparza (olaparib) inhibited survival and proliferation of cells expressing ATM A2524P in a high-throughput cell culture assay (PMID: 40580951). | 40580951 |
| ATM A2524P | prostate cancer | sensitive | Olaparib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) improved progression-free survival (7.4 vs 3.6 mo, HR 0.34, p<0.001), objective response rate (33% vs 2%, OR 20.86, p<0.001), and median overall survival (18.5 vs 15.1 mo, HR 0.64, p=0.02) over control in metastatic prostate cancer patients harboring inactivating BRCA/ATM mutations as detected by approved assays, including ATM A2524P, HR was 1.04 in ATM-mutant group (PMID: 32343890; NCT02987543). | 32343890 detail... detail... |
| ATM A2524P | prostate cancer | sensitive | Enzalutamide + Talazoparib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM A2524P (PMID: 42223064; NCT04821622). | detail... detail... 42223064 |